Ewa LLC Acquires Shares of 1,506 Glaukos Co. (NYSE:GKOS)

Ewa LLC bought a new position in shares of Glaukos Co. (NYSE:GKOS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,506 shares of the medical instruments supplier’s stock, valued at approximately $209,000.

Other institutional investors have also modified their holdings of the company. Values First Advisors Inc. acquired a new stake in Glaukos during the 3rd quarter valued at approximately $25,000. Harvest Fund Management Co. Ltd grew its position in shares of Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 860 shares in the last quarter. Fifth Third Wealth Advisors LLC bought a new stake in shares of Glaukos in the second quarter worth $187,000. KBC Group NV raised its holdings in Glaukos by 16.2% in the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 201 shares in the last quarter. Finally, Brighton Jones LLC bought a new position in Glaukos during the 2nd quarter valued at $208,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

GKOS has been the subject of several research analyst reports. Stifel Nicolaus boosted their target price on shares of Glaukos from $145.00 to $153.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. BTIG Research boosted their price target on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Stephens upgraded Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group started coverage on shares of Glaukos in a report on Friday. They set a “buy” rating and a $182.00 target price on the stock. Finally, Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a research report on Monday, December 2nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $140.00.

Glaukos Trading Up 3.4 %

NYSE:GKOS opened at $140.28 on Monday. Glaukos Co. has a 1 year low of $59.58 and a 1 year high of $146.86. The business has a fifty day moving average of $135.17 and a 200-day moving average of $125.97. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The business had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The business’s revenue for the quarter was up 23.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.50) earnings per share. As a group, sell-side analysts forecast that Glaukos Co. will post -1.89 earnings per share for the current year.

Insiders Place Their Bets

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of Glaukos stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. The trade was a 2.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.40% of the stock is owned by company insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.